October 28, 2015 | Israeli bio-medical company SmartZyme has raised $4 million from healthcare investment fund Orbimed. The new injection of capital will enable the company to further develop their platform for protein design, which the team is currently using to build a glucose monitoring system, as well as other diabetes treatments. Founded in 2013 and run by CEO and Co-Founder Shilo Ben-Zeev, SmartZyme holds offices in Minneapolis, Minnesota and Ness Ziona, Israel.
Related posts
Israel Invests Millions To Help AI Comprehend Hebrew, Arabic
September 21, 2023
Cybersecurity Startup Cato Raises $238M With $3B Valuation
September 21, 2023
Israel, UK Ink Deal For Greater Innovation Collaboration
September 21, 2023
ALS Drug Receives Patent In Israel, Europe, Japan
September 20, 2023
Facebook comments